PT  - JOURNAL ARTICLE
AU  - Isa, Flonza
AU  - Forleo-Neto, Eduardo
AU  - Meyer, Jonathan
AU  - Zheng, Wenjun
AU  - Rasmussen, Scott
AU  - Armas, Danielle
AU  - Oshita, Masaru
AU  - Brinson, Cynthia
AU  - Folkerth, Steven
AU  - Faria, Lori
AU  - Heirman, Ingeborg
AU  - Sarkar, Neena
AU  - Musser, Bret J.
AU  - Bansal, Shikha
AU  - O’Brien, Meagan P.
AU  - Turner, Kenneth C.
AU  - Ganguly, Samit
AU  - Mahmood, Adnan
AU  - Dupljak, Ajla
AU  - Hooper, Andrea T.
AU  - Hamilton, Jennifer D.
AU  - Kim, Yunji
AU  - Kowal, Bari
AU  - Soo, Yuhwen
AU  - Geba, Gregory P.
AU  - Lipsich, Leah
AU  - Braunstein, Ned
AU  - Yancopoulos, George D.
AU  - Weinreich, David M.
AU  - Herman, Gary A.
AU  - ,
TI  - Repeat Subcutaneous Administration of REGEN-COV<sup>®</sup> in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19
AID  - 10.1101/2021.11.10.21265889
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.10.21265889
4099  - http://medrxiv.org/content/early/2021/12/15/2021.11.10.21265889.short
4100  - http://medrxiv.org/content/early/2021/12/15/2021.11.10.21265889.full
AB  - Background Data show that a single dose of casirivimab and imdevimab (REGEN-COV®) is effective in treating hospitalized individuals and outpatients with COVID-19 and in post-exposure prophylaxis. We present results from a phase 1, double-blind, placebo-controlled trial evaluating the safety, tolerability, and efficacy of repeat monthly doses of subcutaneous (SC) REGEN-COV in uninfected adult volunteers who were healthy or had chronic stable medical conditions.Methods Subjects were randomized (3:1) to SC REGEN-COV 1200 mg or placebo dosed every 4 weeks for up to 6 doses. The primary and secondary endpoints evaluated the safety, pharmacokinetics, and immunogenicity of multiple-dose administration of REGEN-COV. Efficacy was evaluated by the incidence of COVID-19 or SARS-CoV-2 seroconversion.Results In total, 969 subjects were treated. Repeat monthly dosing of SC REGEN-COV led to a 92.4% relative risk reduction in clinically-defined COVID-19 compared to placebo (3/729 [0.4%] vs 13/240 [5.4%]; odds ratio: 0.07 [95% CI, 0.01–0.27]), and a 100% reduction in laboratory-confirmed COVID-19 (0/729 vs 10/240 [4.2%]; odds ratio 0.00). Development of anti-drug antibodies was low (<5% subjects). No grade ≥3 injection-site reactions (ISRs) or hypersensitivity reactions were reported. A slightly higher percentage of subjects reported TEAEs with REGEN-COV (54.9%) than placebo (48.3%), due to ISRs (all grade 1-2). Serious adverse events were rare and occurred at similar percentages in the REGEN-COV and placebo groups. No deaths were reported in the 6-month treatment period.Conclusions Repeated monthly administration of 1200 mg SC REGEN-COV was well-tolerated with low immunogenicity, and showed a substantial risk reduction in COVID-19 occurrence.(ClinicalTrials.gov identifier, NCT04519437)Competing Interest StatementICMJE disclosure forms provided by the authors are available with the full text of this article.Clinical TrialNCT04519437Funding StatementSupported by Regeneron Pharmaceuticals, Inc. Certain aspects of this project have been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under OT number HHSO100201700020C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Western Institutional Review Board, Puyallup, WA, USA.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/. https://vivli.org/